Global X Copper Miners ETF vs IDEXX Laboratories, Inc. — how do they compare? Global X Copper Miners ETF trades at $88.5, while IDEXX Laboratories, Inc. trades at $572.92 (market cap $46.22B). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| COPX | IDXX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $766.68 |
52-Week Low | $46.08 | $526.44 |
Market Cap | — | $46.22B |
Enterprise Value | — | $47.12B |
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $89.43, down slightly by 0.09% today. The technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels indicating overbought conditions. Recent news highlights institutional accumulation, with 180 Wealth Advisors increasing its stake by 28.1% in Q2 2026 (SEC filing, August 6, 2026). The ETF is positioned to benefit from copper demand driven by AI infrastructure and electrification trends.
The investment case for COPX hinges on structural copper demand growth from AI data centers and green energy, though it faces risks from commodity price volatility and mining supply constraints. Analysts view the recent pullback as a buying opportunity, citing operational leverage to copper prices. Key risks include cyclical mining downturns and execution challenges among constituent companies.
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Trailing returns across standard periods
Latest headlines on both assets
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →